Cover Image
市場調查報告書

D&A Pharma SAS的產品平台分析

D&A Pharma SAS - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 307309
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
D&A Pharma SAS的產品平台分析 D&A Pharma SAS - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 22 Pages
簡介

D&A Pharma SAS是總公司設置於法國的製藥企業,致力於開發及銷售發揮新功效和效果的創新治療藥。酒精或藥物中毒的適應藥,以及提供可提升API的生物學效果和藥物動力學、防止誤用、針對標的的穩定釋藥用劑形之開發服務。

本報告提供D&A Pharma SAS 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

D&A Pharma SAS 基本資料

  • D&A Pharma SAS 概要
  • 主要資訊
  • 企業資料

D&A Pharma SAS :R&D概要

  • 主要的治療範圍

D&A Pharma SAS :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

D&A Pharma SAS :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

D&A Pharma SAS:藥物簡介

  • MAL
  • sodium oxybate IR
  • ASB
  • sodium oxybate MR

D&A Pharma SAS :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

D&A Pharma SAS :開發被休止了的計劃

D&A Pharma SAS :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06933CDB

Summary

Global Markets Direct's, 'D&A Pharma SAS - Product Pipeline Review - 2015', provides an overview of the D&A Pharma SAS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of D&A Pharma SAS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of D&A Pharma SAS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of D&A Pharma SAS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the D&A Pharma SAS's pipeline products

Reasons to buy

  • Evaluate D&A Pharma SAS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of D&A Pharma SAS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the D&A Pharma SAS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of D&A Pharma SAS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of D&A Pharma SAS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of D&A Pharma SAS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • D&A Pharma SAS Snapshot
    • D&A Pharma SAS Overview
    • Key Information
    • Key Facts
  • D&A Pharma SAS - Research and Development Overview
    • Key Therapeutic Areas
  • D&A Pharma SAS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • D&A Pharma SAS - Pipeline Products Glance
    • D&A Pharma SAS - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • D&A Pharma SAS - Drug Profiles
    • MAL
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sodium oxybate IR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASB
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sodium oxybate MR
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • D&A Pharma SAS - Pipeline Analysis
    • D&A Pharma SAS - Pipeline Products by Target
    • D&A Pharma SAS - Pipeline Products by Route of Administration
    • D&A Pharma SAS - Pipeline Products by Molecule Type
    • D&A Pharma SAS - Pipeline Products by Mechanism of Action
  • D&A Pharma SAS - Dormant Projects
  • D&A Pharma SAS - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • D&A Pharma SAS, Key Information
  • D&A Pharma SAS, Key Facts
  • D&A Pharma SAS - Pipeline by Indication, 2015
  • D&A Pharma SAS - Pipeline by Stage of Development, 2015
  • D&A Pharma SAS - Monotherapy Products in Pipeline, 2015
  • D&A Pharma SAS - Phase II, 2015
  • D&A Pharma SAS - Phase I, 2015
  • D&A Pharma SAS - Pipeline by Target, 2015
  • D&A Pharma SAS - Pipeline by Route of Administration, 2015
  • D&A Pharma SAS - Pipeline by Molecule Type, 2015
  • D&A Pharma SAS - Pipeline Products by Mechanism of Action, 2015
  • D&A Pharma SAS - Dormant Developmental Projects,2015
  • D&A Pharma SAS, Other Locations

List of Figures

  • D&A Pharma SAS - Pipeline by Top 10 Indication, 2015
  • D&A Pharma SAS - Pipeline by Stage of Development, 2015
  • D&A Pharma SAS - Monotherapy Products in Pipeline, 2015
  • D&A Pharma SAS - Pipeline by Top 10 Target, 2015
  • D&A Pharma SAS - Pipeline by Top 10 Route of Administration, 2015
  • D&A Pharma SAS - Pipeline by Top 10 Molecule Type, 2015
  • D&A Pharma SAS - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top